Rigel Reports Strong Q2 with $67M Net Product Sales, Raises 2026 Revenue Guidance to $285-$295M
RIGL sits 89% above its 52-week low of $21.81.
Summary
Rigel Pharmaceuticals reported Q2 2026 net product sales of $67 million, up 14% YoY, and raised its full-year revenue guidance to $285-$295 million. The company expects to launch VEPPANU in mid-August and remains on track for R289 Phase 1b milestones in H2 2026.
Key Events · Earnings and Guidance · RIGL
-
Q2 2026 Financial Results
Total revenues of $78.7M, including net product sales of $67.0M (up 14% YoY) and contract revenues of $11.7M. Net income was $17.3M, or $0.88 per diluted share.
-
Raised 2026 Revenue Guidance
Full-year total revenue guidance increased to $285-$295M, from $275-$290M, with net product sales of $255-$265M and contract revenues of ~$30M. Excludes VEPPANU contribution.
-
VEPPANU Launch Imminent
VEPPANU (vepdegestrant), the first FDA-approved PROTAC for ER+/HER2- ESR1-mutated metastatic breast cancer, expected to be commercially available in the U.S. in mid-August 2026.
-
R289 Clinical Progress
Phase 1b study in lower-risk MDS on track to complete dose expansion enrollment and select recommended Phase 2 dose in H2 2026, with preliminary data by year-end.
Analysis · RIGL · Life Sciences
Rigel delivered a solid second quarter, with net product sales rising 14% year-over-year to $67 million and net income of $17.3 million. The company raised its full-year 2026 revenue guidance to $285-$295 million, driven by continued commercial momentum across its hematology/oncology portfolio. The imminent U.S. launch of VEPPANU in mid-August adds a new growth driver, while the R289 program remains on track for key milestones in the second half of 2026. Cash declined to $95.3 million following the $70 million upfront payment for VEPPANU, but the company expects to remain profitable for the full year.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RIGL was trading at $41.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $716M. The 52-week trading range was $21.81 to $52.24. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.